GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro

Signal Transduct Target Ther. 2020 Nov 17;5(1):267. doi: 10.1038/s41392-020-00391-5.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19 / genetics
  • COVID-19 / immunology*
  • COVID-19 / virology
  • COVID-19 Drug Treatment
  • Cytokine Release Syndrome / immunology
  • Cytokine Release Syndrome / prevention & control*
  • Cytokines / genetics
  • Cytokines / immunology
  • Gene Expression Regulation / drug effects
  • Histone Demethylases / antagonists & inhibitors*
  • Histone Demethylases / genetics
  • Histone Demethylases / immunology
  • Humans
  • Pandemics
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / virology
  • Respiratory Distress Syndrome / drug therapy
  • Respiratory Distress Syndrome / virology
  • SARS-CoV-2 / drug effects*
  • SARS-CoV-2 / immunology
  • SARS-CoV-2 / pathogenicity
  • Sepsis / drug therapy
  • Sepsis / virology

Substances

  • Cytokines
  • Histone Demethylases
  • KDM1A protein, human